Mirabegron Zentiva (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor muscle of the bladder. Activation raises cyclic AMP levels, causing the muscle to relax during the filling phase, which expands bladder capacity and reduces involuntary contractions that trigger urgency.

The dosage of Mirabegron Zentiva is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) than antimuscarinics such as oxybutynin. It generally has a lower incidence of dry mouth and constipation, but may raise blood pressure. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Mirabegron Zentiva tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and heat. Keep the container tightly closed and out of direct sunlight.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include significant hypertension, urinary retention, tachycardia, angioedema and rare cases of anaphylaxis. Patients should seek immediate medical attention if they experience severe headache, rapid heartbeat, difficulty urinating or swelling of the face or throat.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe renal impairment, or known hypersensitivity to mirabegron or any tablet excipients. Caution is also advised for individuals with a history of urinary retention or cardiac arrhythmias.